Table 1.
Baseline Characteristics of Patients Who Underwent Induction or CC Plus IMRT
| The Original Unmatched Cohort |
The Propensity-Matched Cohort |
|||||||
|---|---|---|---|---|---|---|---|---|
| IC + IMRT (n = 94) |
IMRT + CC (n = 302) |
P | Standardized Difference | IC + IMRT (n = 94) |
IMRT + CC (n = 94) |
P | Standardized Difference | |
| No. (%) | No. (%) | No. (%) | No. (%) | |||||
| Age | .872 | 0.018 | .548 | 0.087 | ||||
| Mean | 44.99 | 45.19 | 44.99 | 44.01 | ||||
| SD | 11.59 | 10.34 | 11.59 | 10.69 | ||||
| Median | 44.50 | 45.00 | 44.50 | 43.50 | ||||
| Sex | .904 | 0.014 | .866 | 0.025 | ||||
| Male | 70 (74.5) | 223 (73.8) | 70 (74.5) | 71 (75.5) | ||||
| Female | 24 (25.5) | 79 (26.2) | 24 (25.5) | 23 (24.5) | ||||
| Histology* | .461 | 0.091 | 1.000 | 0.000 | ||||
| II | 4 (4.3) | 19 (6.3) | 4 (4.3) | 4 (4.3) | ||||
| III | 90 (95.7) | 283 (93.7) | 90 (95.7) | 90 (95.7) | ||||
| T stage | .050 | .978 | ||||||
| T1 | 7 (7.4) | 31 (10.3) | 0.099 | 7 (7.4) | 7 (7.4) | 0.000 | ||
| T2 | 15 (16.0) | 59 (19.5) | 0.094 | 15 (16.0) | 13 (13.8) | 0.060 | ||
| T3 | 34 (36.2) | 135 (44.7) | 0.175 | 34 (36.2) | 36 (38.3) | 0.044 | ||
| T4 | 38 (40.4) | 77 (25.5) | 0.322 | 38 (40.4) | 38 (40.4) | 0.000 | ||
| N stage | .124 | .985 | ||||||
| N0 | 14 (14.9) | 43 (14.2) | 0.019 | 14 (14.9) | 13 (13.8) | 0.030 | ||
| N1 | 50 (53.2) | 197 (65.2) | 0.247 | 50 (53.2) | 52 (55.3) | 0.043 | ||
| N2 | 23 (24.5) | 46 (15.2) | 0.233 | 23 (24.5) | 23 (24.5) | 0.000 | ||
| N3 | 7 (7.4) | 16 (5.3) | 0.088 | 7 (7.4) | 6 (6.4) | 0.042 | ||
| Clinical stage | .004 | 1.000 | 0.000 | |||||
| II | 10 (10.6) | 69 (22.8) | 0.331 | 10 (10.6) | 10 (10.6) | |||
| III | 40 (42.6) | 140 (46.4) | 0.077 | 40 (42.6) | 40 (42.6) | |||
| IV | 44 (46.8) | 93 (30.8) | 0.333 | 44 (46.8) | 44 (46.8) | |||
⁎
Based on the criteria of WHO histological type (1991): II, differentiated nonkeratinizing carcinoma; III, undifferentiated nonkeratinizing carcinoma.